No adequate and well controlled studies in pregnant woman. This drug should be used in pregnant woman only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when (olopatadine hydrochloride ophthalmic solution) 0.1% is administered to a nursing mother.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
